HOUSTON, June 22, 2018 /PRNewswire/ --
India-Based APAC Biotech and US-Based Diakonos Research sign a
first-of-its-kind technology transfer and licensing agreement to
bring new immunotherapy technology to India as an advancement of immuno-oncology
therapeutics for solid tumors.
(Logo:
http://mma.prnewswire.com/media/486747/APAC_Biotech_Logo.jpg
)
This new path breaking technology effectively targets and
activates the tumor antigen specific CTL-response and is
differentiated from peer technologies in its ability to generate
durable immunological memory. On the basis of pre-clinical animal
data shared by Dr. William Decker
and his research team at Baylor College of
Medicine, APAC Biotech plans to launch phase II clinical
trials in India for advanced brain
and pancreatic cancers, that have limited treatment options.
"We are committed to accelerating the availability of novel
immuno-oncology treatments to patients with high unmet medical
needs in India and around the
globe," said Mr. Arun K. Mehra, CEO,
APAC Biotech Pvt. Ltd, the new long-term memory potentiation
technology is a highly promising, best-in-class cancer
immunotherapy anticipated to improve outcomes even further. APAC
management is in talks with large investors for production scale-up
of currently approved products and future clinical development
trials.
About APAC Biotech
A leading biotechnology company in India involved in research and manufacturing
of Dendritic cell-based immunotherapy for the treatment of cancer
since over a decade. Their product APCEDEN® was developed after a
thorough research based on the principles of Immunology. In the
trials conducted by APAC Biotech in the past with APCEDEN®, an
overall response of 42.1 % (irRC) was demonstrated in patients with
advanced refractory solid cancers and APCEDEN® was approved by the
Indian FDA in March 2017.
About Diakonos Research, Ltd.
A development-stage immuno-oncology partnership founded in
2015 to commercialize basic research discoveries made in the Texas
Medical Center. The company holds multiple licensing agreements
with Baylor College of Medicine and an
extensive worldwide IP portfolio in the immuno-oncology space.
Diakonos is pursuing US-based clinical development strategies with
novel innate signaling, CAR T-cell, and cell-based vaccine
strategies while simultaneously capitalizing upon strategic
partnerships in foreign marketplaces.
This press release contains 'forward-looking' statements,
including statements regarding the conduct of clinical trials.
Actual results may differ materially from those set forth in this
press release due to the risks and uncertainties inherent in
healthcare development. APAC Biotech undertakes no obligation to
revise or update information herein to reflect events or
circumstances in the future, even if new information becomes
available.
Contact
Dr. Bandana Sharan
+91-124-4207575
drbandana@apacbiotech.com